D
uring the past 2 decades, cardiac resynchronization therapy (CRT) utilizing biventricular pacing (BVP) has emerged as an effective therapy for patients with cardiomyopathy, reduced left ventricular (LV) ejection fraction (LVEF), heart failure (HF), and a wide QRS. Multiple prospective randomized studies have shown that BVP improves quality of life, increases exercise capacity, reduces HF hospitalization (HFH), and decreases all-cause mortality, particularly in patients with a left bundle branch block (LBBB). [1] [2] [3] [4] [5] [6] However, in comparison to patients with LBBB, those with right bundle branch block (RBBB) do not seem to derive a similar benefit from BVP. 7 Some studies suggest that patients with a wide RBBB and more advanced HF may benefit from BVP. 8 Based on these data, current guidelines provide a Class IIa recommendation for patients with RBBB and QRS duration ≥150 ms and a IIb recommendation for patients with RBBB and QRS duration of 120 to 150 ms. 9 Permanent His bundle pacing (HBP) has recently emerged as an option to deliver physiological ventricular pacing. Permanent HBP has been shown to overcome bundle branch block (BBB), including RBBB, and is being considered as a viable alternative to BVP in patients requiring CRT. [10] [11] [12] [13] [14] The number of patients with RBBB in these studies was small. The aim of this study was to assess the feasibility and outcomes of HBP among patients with reduced LVEF and RBBB.
METHODS

Patient Selection
Permanent HBP was attempted in patients with RBBB, QRS duration (QRSd) ≥120 ms, New York Heart Association (NYHA) class II to IV HF symptoms and a baseline LVEF ≤50%. For patients who qualified for a CRT device based on current recommendations, HBP was attempted as a primary strategy (first line instead of a coronary sinus lead) or as a rescue strategy (in patients who failed coronary sinus lead placement). In patients without an indication for CRT (LVEF >35%), single or dual-chamber pacemakers were used as clinically indicated.
Sites Included
This is a retrospective, observational multicenter study and included 5 sites: Geisinger Wyoming Valley Medical Center, Rush University Medical Center, Chinese University of Hong Kong, Imperial College London, and Virginia Commonwealth University. All implanters had significant experience in permanent HBP. Patients provided informed consent and demonstrated an understanding of HBP as a nonstandard approach to achieve cardiac resynchronization. Data analysis was approved by the institutional review board at each site. The data that support the findings of this study are available from the corresponding author on reasonable request.
Procedural Details
HBP was performed using the SelectSecure pacing lead (model 3830, 69 cm; Medtronic, Inc, Minneapolis, MN) as previously described. 11 The lead was delivered through a fixed curve sheath (C315HIS; Medtronic, Inc, Minneapolis, MN) or a deflectable sheath (C304; Medtronic, Inc, Minneapolis, MN). His bundle (HB) electrograms were mapped with the pacing lead in unipolar fashion and recorded with Medtronic pacing system analyzer (model 2290) and on an electrophysiology recording system based on the operator's preference. The HB region was carefully mapped until pacing resulted in HB capture with or without correction of RBBB. The lead was then fixed at the optimal position by means of 4 to 5 clockwise rotations. The HB capture thresholds and bundle branch correction thresholds were assessed and recorded at a pulse width of 1.0 ms. If an acceptable HB capture could not be achieved after 5 attempts of lead positioning or a fluoroscopy duration of 20 minutes, it was considered a failure. When an HB electrogram was not recordable during mapping, pace-mapping was performed in a unipolar fashion to identify the successful site. If primary HBP was unsuccessful in patients with indication for CRT, an LV lead was implanted in the coronary venous branches.
Follow-Up
Patients were followed in the device clinic at 2 weeks, 3 months, and 1 year and by remote monitoring every 3 months. R-wave amplitudes, capture thresholds, lead impedance, type of HB pacing, and percentage of ventricular pacing were recorded at each visit. All capture thresholds were defined using a pulse width of 1 ms. Output required to maximally narrow the QRS in addition to His capture threshold was documented by 12 lead ECGs. Lead-related complications were routinely tracked. Echocardiograms were analyzed by cardiologists blinded to the type of device implanted. Echocardiographic indices, including LVEF, LV end-diastolic dimensions, pulmonary artery systolic pressure, and right ventricular (RV) internal diameter were recorded preimplant and at follow-up. Clinical outcomes
WHAT IS KNOWN?
• The clinical benefits of biventricular pacing are limited in patients with right bundle branch block and cardiomyopathy.
• Recent studies have suggested His bundle pacing to be an alternative to biventricular pacing in patients with left bundle branch block and cardiomyopathy.
WHAT THIS STUDY ADDS?
• His bundle pacing was effective in achieving electric resynchronization in patients with right bundle branch block and cardiomyopathy.
• His bundle pacing may improve left ventricular ejection fraction and heart failure symptoms in these patients.
tracked included new-onset atrial fibrillation (AF), HFH, and all-cause mortality. Mortality outcome data were collected from hospital records or social security death index.
Definitions
1. Selective or nonselective HBP was determined based on previously published criteria 15, 16 : Selective HBP (S-HBP) was defined as ventricular activation occurring exclusively via His-Purkinje system as evidenced by a QRS morphology identical to baseline (without correction of BBB) or significantly narrower (correction of BBB). In these patients, there was an isoelectric segment between the pacing stimulus and QRS onset. The local ventricular electrogram on the His lead was discrete from the pacing artifact because direct myocardial capture did not occur and, therefore, the ventricular activation wavefront proceeded from apex to base ( Figure I in the Data Supplement). When there was BBB correction, there was a visible change in the morphology of the local electrogram recorded from the HBP lead. 2. Nonselective HBP (NS-HBP) was defined on the basis of capture of basal ventricular septum in addition to HB capture ( Figure II in the Data Supplement). In these patients, usually, there was no isoelectric interval between the pacing stimulus and QRS onset. In addition, electrogram inscription in the HBP lead was not delayed because of the immediate capture of the local myocardium. In patients with NS-HBP and correction of RBBB, the stimulus to the QRS end is shorter than the His-QRS end . In these patients, 3 distinct pacing responses may be observed (HB capture with RBBB correction, HB capture without correction, and RV capture). In patients without BBB correction, complete or partial resolution of RBBB pattern may occur because of septal fusion, in which case a smaller terminal R wave may persist in the surface lead V1. In this situation, the paced QRS duration may be less than or occasionally greater than the baseline QRS duration depending on the underlying HV interval ( Figure IIIB in the Data Supplement). 3. RBBB correction with fusion. In some patients with S-HBP without correction of RBBB, significant narrowing of QRS duration was achieved by ventricular fusion utilizing His-sequential RV pacing (His to RV delay programmed at stimulus-ventricular (equal to HV) interval during HBP; Figure III in the Data Supplement). Thus, the 3 groups of patients studied included (1) S-HBP with narrowing of RBBB, (2) NS-HBP with narrowing of RBBB, and 3) HBP with RV fusion (using RV lead) resulting in overcoming RBBB.
Echocardiographic response was defined as a ≥5% increase in LVEF. Super response was defined as an absolute improvement in LVEF by ≥20% or improvement of LVEF to >50% (in patients with LVEF ≤35%) between baseline and follow-up echocardiograms. 17 Clinical response to CRT was defined as an improvement in NYHA functional class by 1 class and no HFH. 17 HFH was defined as a hospital admission or an urgent care visit for intensive treatment for HF with intravenous diuretics or intravenous inotropic medications. New-onset AF was defined as at least 6 minutes of continuous AF as documented by the device log.
Statistical Analysis
Continuous variables were reported as mean±SD. Paired comparisons were made using a paired t test if the data were normally distributed and with the McNemar test for nonparametric data. Paired categorical data were compared using the McNemar test. P value ≤0.05 was considered significant. The SPSS 24 software (IBM, NY) was used for data analysis.
RESULTS
A total of 39 patients underwent an attempt at HBP at 5 centers. HBP was successful in 37 patients with an overall success rate of 95%. Patients were followed for an average duration of 15±23 months (median, 9 months; range, 0-53 months). Three patients were lost to follow-up.
Baseline Characteristics
Baseline characteristics of the study population are shown in Table 1 . Mean age of the patients was 72±10 years with 15% females. All patients had cardiomyopathy at baseline with mean LVEF of 31±10% (69% of patients had LVEF ≤35% and 31% had LVEF between 35% and 50%). Seventy-two percent of patients had NYHA functional class III to IV. Forty-six percent of patients had ischemic cardiomyopathy. Fifty-eight percent (24 patients) had underlying RBBB alone, 18% of patients had second or third degree AV block with RBBB, and 20% (8 patients) had a ventricular paced rhythm with underlying RBBB (upgrade to CRT). Baseline QRSd of the entire cohort was 158±23 ms, whereas the RV paced QRSd was 196±28 ms.
Feasibility and Safety
The overall success rate for HBP in patients with RBBB was 95%. HBP resulted in RBBB correction in 29 (78%) patients (BBB correction group), whereas the remaining 22% of patients had a narrower paced QRSd because of fusion between HBP and RV pacing (NS-HBP without BBB correction or S-HBP and RV synchronous pacing). Recruitment of the right bundle branch was noted in 83% of the ischemic (15 of 18 patients) and 74% of nonischemic cardiomyopathy patients (14 of 19, P=0.7). HBP was successful as a primary strategy in 32 of 34 attempted patients (94%) and as a rescue strategy (after a failed attempt at coronary sinus lead implant) in 5 of 5 (100%) patients. Eight of the 37 patients underwent successful HBP for high burden of RV pacing with underlying RBBB.
Procedural outcomes are presented in Table 2 . Seventy percent of patients received a CRT device (implantable cardioverter defibrillator [ICD], 77% and pacemaker, 23%), whereas the remainder (26%) received a dual-chamber or single-chamber device (pacemaker, 91%; ICD, 9%). In most patients receiving a CRT device, the HBP lead was connected to the LV port. In patients with RBBB recruitment, the LV to RV offset was increased maximally resulting in functional noncapture of the RV lead. In patients without RBBB recruitment (n=8), the LV-RV timing was programmed to generate the narrowest fused QRS, fusing the His (activation via left bundle branch) and RV pacing wavefronts ( Figure III in the Data Supplement). S-HBP with QRS narrowing (RBBB recruitment) was achieved in 10 (34%) patients and NS-HBP in 19 (66%) patients. Overall HB capture threshold was 1.1±0.6 V at 1 ms at implant and increased to 1.3±0.9 V at 1 ms at a mean follow-up of 15±23 months (P=0.6). Threshold for narrowing of BBB was 1.4±0.7 V at 1 ms at implant and 1.6±2.4 V at 1 ms during follow-up (P=0.6). No immediate procedure-related complications were noted.
An increase in HB capture threshold (defined as a ≥1 V increase in capture threshold from implant) was noted in 3 (9%) cases, 1 of which resulted in loss of BBB recruitment at maximum programmable outputs. Repeat procedures were needed in 1 patient (replacement of the His lead with an LV lead), and others were managed conservatively by increasing HBP outputs. One patient moved out-of-state and was reported to have lost RBBB correction. One patient developed pocket infection at 2 months and required explant of the system with a successful reimplant with HBP (3 months post explant).
ECG and Echocardiographic Parameters
Overall, QRSd decreased significantly from 158±24 ms at baseline to 127±17 ms (P=0.0001). Patients with underlying ventricular pacing at baseline also had a significant narrowing of paced QRSd (198±27-141±16 ms; P=0.0002; Table 3 ; Figure 1 ). Follow-up echocardiographic data were available for 70% patients. Echocardiographic response (>5% improvement in LVEF) was noted in 69% cases. Overall LVEF improved significantly from 31±10% at baseline to 39±13% at follow-up (P=0.0001). Among patients with LVEF ≤35%, LVEF improved significantly from 26±7% to 34±12% (P=0.0001). Five patients (19%) were super-responders ( Figure IV in the Data Supplement). There was no significant change in LV end-diastolic dimensions during follow-up (57±7-56±10 mm, P=0.4). In addition, no significant differences were noted in RV internal dimensions (P=0.4) or pulmonary artery systolic pressures (P=0.5) with permanent HBP.
Clinical Outcomes
Clinical response (improvement in 1 NYHA functional class and no HFH) to HBP was noted in 76% patients. There was a significant improvement in overall NYHA functional class from 2.8±0.6 at baseline to 2.0±0.7 on follow-up (P<0.0001). The mean follow-up period was 15±23 months; during this time 2 patients were admitted with HFH (6%), 2 patients developed new-onset AF (6%), and 2 patients (6%) died (malignancy 1, stroke/ infection/sepsis 1).
Response Rates to HBP for CRT in RBBB
Of the 37 patients in whom His pacing was successfully delivered, a clinical response to HBP was observed in 76%, whereas in 69% an echocardiographic response was observed, with super response in 20% of patients. There were no significant differences in clinical (71% versus 77%) or echocardiographic response (71% versus 68%) between the baseline RV paced group (N=8) versus the non-RV paced group (N=29; P=1.0; Figure 1 ) Among patients with a baseline QRSd between 120 and 150 ms (N=20), clinical response was noted in 15 of 19 patients (79%), echocardiographic response in 11 of 16 (69%) and 31% patients were super-responders. Patients who had a baseline QRSd of >150 ms (N=17) demonstrated a clinical response in 71% patients, echocardiographic response in 70% cases, and there were no super-responders.
There were no significant differences in clinical response (73% versus 86%; P=0.7) response or echocardiographic response (79% versus 43%; P=0.2) between the HBP with RBBB recruitment versus the HBP+RV fused group.
In our study, there were 15 patients with a PR <230 ms, 5 patients with PR ≥230 ms, 13 patients with advanced AV block, and 4 patients with chronic AF. Even in patients with PR <230 ms, there were significant clinical and echocardiographic benefits observed with permanent HBP.
DISCUSSION
The main findings of this study are that in patients with cardiomyopathy, reduced LVEF, RBBB, and HF:
1. Permanent HBP resulted in a significant reduction in QRS duration when applied to patients with RBBB and LV impairment. 2. Significant improvements in LVEF and NYHA functional class were observed when HBP was applied to this population. It is well recognized that BVP results in a significant clinical benefit in patients with HF and cardiac dyssynchrony. This benefit is greatest among patients with LBBB and QRS duration ≥150 ms. 7, 8 The impact of QRS morphology and outcomes with CRT was evaluated by Sipahi et al 7 in a meta-analysis of 4 clinical trials. This analysis included 5356 patients and demonstrated no benefit for patients with RBBB conduction abnormalities in comparison to patients with underlying LBBB. The RAFT trial (Resynchronization for Ambulatory Heart Failure Trial) demonstrated that patients with LBBB had a better outcome than non-LBBB patients, but the statistical interaction between benefit and QRS morphology was weak in this trial (P=0.046). 8 Cardiac resynchronization therapy defibrillator was more effective in patients with QRS duration ≥150 ms but of no benefit in patients with QRS duration <150 ms 8 . It should be noted that the composite clinical end-point reported in these studies based on QRS morphology varied slightly across the trials but always included all-cause mortality and HFH. HF hospitalization, n (%) 2 (6) Mortality (noncardiovascular), n (%) 2 (6) AF indicates atrial fibrillation; BBB, bundle branch block; HBP, His bundle pacing; HF, heart failure; LVEDD, left ventricular end diastolic diameter; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PASP, pulmonary artery systolic pressure; QRSd, QRS duration; and RVID, right ventricular internal diameter.
In recent years, the availability of specialized lead and delivery systems has resulted in improved success rates with permanent HBP. It has recently been shown to be a viable alternative to BVP in CRT-indicated patients. [10] [11] [12] [13] [14] 18 HBP can result in correction/recruitment of RBBB and narrowing of the QRS. 12, 19 However, this is the first study evaluating the impact of permanent HBP in a larger group of patients with RBBB and are CRT-indicated based on QRSd and current guidelines. The findings of this study suggest that permanent HBP could be a reasonable strategy in patients with low LVEF, NYHA functional class ≥II with a baseline RBBB. Interestingly, patients with RBBB between 120 and 150 ms also derived benefit from permanent HBP with a clinical and echocardiographic response.
The recently reported ENHANCE-CRT trial (CRT Implant Strategy Using the Longest Electrical Delay for Non-left Bundle Branch Block Patients) 20 randomized 248 patients with non-LBBB pattern and a CRT indication in a 2:1 fashion to QLV-based LV lead implant versus standard of care anatomic LV lead implant. The majority of the patients (58%) had an RBBB, and more than half the patients had a QRS width ≥150 ms. This study demonstrated a 70% response rate (improvement in composite clinical score) to CRT in all comers and no significant difference in benefit between the RBBB and intraventricular conduction defect groups. Our study reports a similar overall clinical and echocardiographic response rate to the ENHANCE-CRT trial. The absence of a control arm in ENHANCE allows only inferential comparisons for end-points like mortality and heart failure. HF with RBBB is physiologically different from that with LBBB. In LBBB, the septum contracts first against a nonactivated free LV wall resulting in dyssynchronous LV contraction. On the contrary, in patients with RBBB, it is the RV that contracts asynchronously with mostly normal LV activation (Figure 2 ). This is evident in LV activation time studies where LV activation time is only minimally increased in RBBB but significantly increased in LBBB. 21 However, in patients undergoing permanent HBP, synchronization of delayed RV activation and normal LV activation is feasible. This can be achieved in 2 ways: (1) Recruitment of RBBB with HBP and normalization of delayed RV activation; and (2) In cases without RBBB recruitment, fusion between HBP (with RBBB pattern) and RV pacing to overcome delayed RV activation. In this small series, there were no significant differences in clinical or echocardiographic response rates between these 2 activation patterns. An additional potential benefit of His pacing in this group is that it does not cause LV dyssynchrony since LV activation occurs via the His-Purkinje system. Whereas LV pacing with BVP, when delivered to patients with preserved activation via the left bundle, results in prolongation of LV activation time relative to sinus rhythm (Figure 3 ).
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Figure 1. Outcomes with His bundle pacing (HBP) in right bundle branch block (RBBB).
A, ECG characteristics demonstrating a statistically significant narrowing of the QRS duration (QRSd) after HBP in the overall population. B, Echocardiographic assessment of left ventricular (LV) ejection fraction (LVEF) pre and post HBP in RBBB again demonstrating a significant improvement in LVEF with HBP irrespective of the baseline LVEF. C, Assessment of clinical and echocardiographic response to HBP in RBBB demonstrating a good response rate in all subgroup (refer to text for more details).
Electric Response to HBP in RBBB
In our series, HBP with RBBB correction was seen in 78% of patients (S-HBP 34% and NS-HBP in 66%). In patients with RBBB, identification of recruitment of latent fascicular tissue during NS-HBP can be particularly challenging. In patients with underlying LBBB, when there is no correction of BBB during NS-HBP, the paced QRS duration is invariably wider than the native QRS, and the dV/dt of the terminal QRS is slow. RV septal fusion with NS-HBP does not result in significant narrowing of the delayed LV activation in LBBB. However, in RBBB, RV septal fusion during NS-HBP can result in partial or complete elimination of the terminal RV conduction delay without recruiting the latent right bundle fascicle (Supplemental Figure III in the Data Supplement). Particular attention to output dependent changes in QRS and local electrogram morphology is helpful in identifying BBB correction.
It is conceivable that in patients with NS-HBP and BBB correction, given that the degree of RV fusion pacing is small, the hemodynamic consequences would be minimal ( Figure 4 ). However in NS-HBP, without RBB recruitment, there would be significant RV preexcitation and non-Purkinje mediated slow electric activation of the entire RV. It is possible that this can lead to adverse RV hemodynamic consequences. Only a small number of patients in our series had HBP without recruitment (8, 22%) . In 3 of these patients with S-HBP without BBB correction ( Figure III fourth panel in the Data Supplement), we had minimized RV preexcitation by sequential RV pacing (His to RV delay) to time the RV activation to coincide with LV activation via His-Purkinje conduction. Although the RV activation is non-Purkinje mediated, the timing of RV activation is synchronous with LV activation via the left bundle branch during HBP. Because of the small number of patients with these pacing characteristics in our study, no meaningful conclusion about their clinical impact could be made.
In a small number of patients, we were able to achieve distal HBP beyond the site of conduction disease. In these patients, the HB capture threshold was the same as the RBBB correction threshold, or the RBB capture threshold was lower than the HBP threshold (Figure V 
Impact of Baseline PR Interval on Outcomes for CRT
Another group of patients that might benefit from CRT among patients with HF and RBBB is patients with firstdegree atrioventricular block. A substudy of the MADIT- CRT trial (Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy) studied 537 patients with a non-LBBB pattern and divided patients into 2 groups based on a PR value of 230 ms. 22 There were 96 patients (22%) with a prolonged PR and 438 patients (78%) with a normal PR interval. In non-LBBB patients with a prolonged PR interval, cardiac resynchronization therapy defibrillator treatment was associated with a 73% reduction in the risk of HF/death (hazard ratio, 0.27; P<0.001) and 81% decrease in the risk of allcause mortality (hazard ratio, 0.19; P<0.001) compared with ICD therapy alone, whereas those with a normal PR, cardiac resynchronization therapy defibrillator therapy were associated with a trend toward an increased risk of HF/death (hazard ratio, 1.45; P=0.078; interaction P value <0.001) and >2-fold higher mortality (hazard ratio, 2.14; P=0.022; interaction P value <0.001) compared with ICD therapy. 23 As noted in our study, even in patients with PR <230 ms, there were significant clinical and echocardiographic benefits observed with permanent HBP.
Limitations
Despite being a multiple center experience, this was a retrospective study involving nonconsecutive patients with possible selection bias. In addition, the high success rates of HBP achieved by experienced operators need to be replicated in prospective studies. Another limitation of the study is the lack of a direct comparison to BVP and the lack of a control arm. Individual data on heart failure management or change in pharmacological therapy was not available and hence we could not assess the impact of this on outcomes. Also, given the retrospective nature of this study, the echocardiographic data were not analyzed at a single core laboratory which is a limitation of the current study. During a mean follow-up of 15 months, HBP threshold remained relatively stable; however, the long-term stability and recruitment of RBBB with HBP in patients with His-Purkinje conduction disease is unknown. Finally, given the relatively small sample number of patients in each subgroup, the study was not adequately powered to assess impact of variables, such as QRSd, PR intervals and selective or NS-HBP on response rates and hence these data should only be used as hypothesis generating for a larger study.
Conclusions
Permanent HBP was feasible with high success rates in patients with RBBB and an indication for CRT. HBP was associated with significant narrowing of QRS duration and improvement in LV function. HBP may be a reasonable alternative for patients with LV impairment and RBBB. Future randomized studies are essential to understand the role of HBP compared with BVP or no pacing in this patient population. 
ARTICLE INFORMATION
